DrugBank 5.0: a major update to the DrugBank database for 2018
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
DrugBank (www.drugbank.ca) is a web-enabled database containing comprehensive molecular information about drugs, their mechanisms, their interactions and their targets. First described in 2006, DrugBank has continued to evolve over the past 12 years in response to marked improvements to web standards and changing needs for drug research and development. This year's update, DrugBank 5.0, represents the most significant upgrade to the database in more than 10 years. In many cases, existing data content has grown by 100% or more over the last update. For instance, the total number of investigational drugs in the database has grown by almost 300%, the number of drug-drug interactions has grown by nearly 600% and the number of SNP-associated drug effects has grown more than 3000%. Significant improvements have been made to the quantity, quality and consistency of drug indications, drug binding data as well as drug-drug and drug-food interactions. A great deal of brand new data have also been added to DrugBank 5.0. This includes information on the influence of hundreds of drugs on metabolite levels (pharmacometabolomics), gene expression levels (pharmacotranscriptomics) and protein expression levels (pharmacoprotoemics). New data have also been added on the status of hundreds of new drug clinical trials and existing drug repurposing trials. Many other important improvements in the content, interface and performance of the DrugBank website have been made and these should greatly enhance its ease of use, utility and potential applications in many areas of pharmacological research, pharmaceutical science and drug education.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“DrugBank primarily contains drug indications extracted from drug labels, while MEDI utilizes public internet sources to drug indications, and is a well utilized resource of drug indications.”
From OnSIDES database: Extracting adverse drug events from drug labels using natural language processing models (2025) · cites this paper as [48]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Finally, we searched DrugBank84 to identify therapeutic compounds targeting AD-associated proteins. Of the 38 proteins, 15 had reported molecules (Fig. 4D).”
From Proteogenomic analysis of human cerebrospinal fluid identifies neurologically relevant regulation and implicates causal proteins for Alzheimer’s disease (2024) · cites this paper as [84]
In the citing paper
“AVPR2 and NPR1 genes play pivotal roles in regulating fluid and electrolyte balance via complementary but distinct pathways. AVPR2 contributes to water retention and urine concentration, whereas NPR1 facilitates vasodilatation, lowers blood pressure and enhances water excretion47.”
From A foundation model for clinician-centered drug repurposing (2024) · cites this paper as [47]
In the citing paper
“In essence, the CC is an alternative representation of the small-molecule knowledge deposited in the public domain and, as such, it is also limited by the availability of experimental data and the coverage of its source databases (e.g., ChEMBL9 or DrugBank10).”
From Bioactivity descriptors for uncharacterized chemical compounds (2021) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DrugBank: a comprehensive resource for in silico drug discovery and exploration
Wishart, D. S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj067 · Cited by 3,892 · cited 1×
“DrugBank 1.0, released in 2006, provided novel (at the time) physico-chemical data on selected FDA-approved drugs and their drug-targets (2).”
BackgroundInfluentialSelf-citationDrugBank: a knowledgebase for drugs, drug actions and drug targets
Wishart, D. S., Knox, C., Guo, A. C., Cheng, D., Shrivastava, S., Tzur, D., Gautam, B., & Hassanali, M. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkm958 · Cited by 2,861 · cited 1×
“DrugBank 2.0, released in 2008, added pharmacological, pharmacogenomic and molecular biological data (3).”
BackgroundInfluentialSelf-citationThe new NHGRI-EBI Catalog of published genome-wide association studies (GWAS Catalog)
MacArthur, J., Bowler, E., Cerezo, M., Gil, L., Hall, P., Hastings, E., Junkins, H., McMahon, A., Milano, A., Morales, J., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1133 · Cited by 2,161 · cited 2×
“org and FDA labels), as well as material collated from sources such as The Human Cytochrome P450 (CYP) Allele Nomenclature Database (12) and the NHGRI-EBI GWAS Catalog (13).”
BackgroundDrugBank 4.0: shedding new light on drug metabolism
Law, V., Knox, C., Djoumbou, Y., Jewison, T., Guo, A. C., Liu, Y., Maciejewski, A., Arndt, D., Wilson, M., Neveu, V., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1068 · Cited by 1,993 · cited 1×
“tion, distribution, metabolism, excretion and toxicity) data (5).”
Self-citationDrugBank 3.0: a comprehensive resource for 'Omics' research on drugs
Knox, C., Law, V., Jewison, T., Liu, P., Ly, S., Frolkis, A., Pon, A., Banco, K., Mak, C., Neveu, V., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1126 · Cited by 1,831 · cited 1×
“DrugBank 3.0, released in 2010, added drug–drug and drug–food interactions, drug transporter data as well as pharmacokinetic information (4).”
BackgroundInfluentialSelf-citationClassyFire: automated chemical classification with a comprehensive, computable taxonomy
Djoumbou Feunang, Y., Eisner, R., Knox, C., Chepelev, L., Hastings, J., Owen, G., Fahy, E., Steinbeck, C., Subramanian, S., Bolton, E., et al. (2016) · Journal of Cheminformatics · doi:10.1186/s13321-016-0174-y · Cited by 1,525
Self-citationThe Comparative Toxicogenomics Database: update 2017
Davis, A. P., Grondin, C. J., Johnson, R. J., Sciaky, D., King, B. L., McMorran, R., Wiegers, J., Wiegers, T. C., & Mattingly, C. J. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw838 · Cited by 544 · cited 1×
“Additional pharmacoproteomic and pharmacotranscriptomic data were obtained from the CTD (18).”
MethodPredicting drug metabolism: experiment and/or computation?
Kirchmair, J., Göller, A. H., Lang, D., Kunze, J., Testa, B., Wilson, I. D., Glen, R. C., & Schneider, G. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4581 · Cited by 502 · cited 1×
“It has also become much more robust and sophisticated (21).”
BackgroundAllen, F., Pon, A., Wilson, M., Greiner, R., & Wishart, D. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku436 · Cited by 464 · cited 7×
“In particular, CFM-ID (19) and CFM-ID 2.”
BackgroundInfluentialSelf-citationSim, S. C., & Ingelman-Sundberg, M. (2010) · Human Genomics · doi:10.1186/1479-7364-4-4-278 · Cited by 216 · cited 2×
“org and FDA labels), as well as material collated from sources such as The Human Cytochrome P450 (CYP) Allele Nomenclature Database (12) and the NHGRI-EBI GWAS Catalog (13).”
Background
Cited by
Metascape provides a biologist-oriented resource for the analysis of systems-level datasets
Zhou, Y., Zhou, B., Pache, L., Chang, M., Khodabakhshi, A. H., Tanaseichuk, O., Benner, C., & Chanda, S. K. (2019) · Nature Communications · doi:10.1038/s41467-019-09234-6 · Cited by 14,611
Sherman, B. T., Hao, M., Qiu, J., Jiao, X., Baseler, M. W., Lane, H. C., Imamichi, T., & Chang, W. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac194 · Cited by 6,142
PubChem in 2021: new data content and improved web interfaces
Kim, S., Chen, J., Cheng, T., Gindulyte, A., He, J., He, S., Li, Q., Shoemaker, B. A., Thiessen, P. A., Yu, B., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkaa971 · Cited by 3,953
PubChem 2019 update: improved access to chemical data
Kim, S., Chen, J., Cheng, T., Gindulyte, A., He, J., He, S., Li, Q., Shoemaker, B. A., Thiessen, P. A., Yu, B., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1033 · Cited by 3,249
“The Target View page also presents known drugs and curated ligands, collected from ChEMBL (9), DrugBank (10) and IUPHAR / BPS Guide to PHARMACOLOGY (11).”
BackgroundCARD 2020: Antibiotic Resistome Surveillance with the Comprehensive Antibiotic Resistance Database
Alcock, B. P., Raphenya, A. R., Lau, T. T. Y., Tsang, K. K., Bouchard, M., Edalatmand, A., Huynh, W., Nguyen, A.-L. V., Cheng, A. A., Liu, S., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz935 · Cited by 3,202
HMDB 5.0: the Human Metabolome Database for 2022
Wishart, D. S., Guo, A., Oler, E., Wang, F., Anjum, A., Peters, H., Dizon, R., Sayeeda, Z., Tian, S., Lee, B. L., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkab1062 · Cited by 2,519
“In addition, HMDB’s ChemoSummarizer (a program that has been used to auto-describe compounds in the HMDB since 2017) was modified and upgraded to incorporate more chemical/biological data, to extract data from DrugBank (19) and MarkerDB (20) and to generate more informative descriptions.”
Self-citationMolecular Docking: Shifting Paradigms in Drug Discovery
Pinzi, L., & Rastelli, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184331 · Cited by 2,344
“For example, Luo et al. [138] performed an extensive study on more than 1200 compounds extracted from DrugBank against 600 human proteins for predicting or rationalizing drug adverse effects.”
MethodInfluentialZhou, G., Soufan, O., Ewald, J., Hancock, R. E. W., Basu, N., & Xia, J. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz240 · Cited by 1,899
“DrugBank is a public database specialized in drug molecular information, mechanisms of action and drug-target information for > 10 000 drugs.”
BackgroundDrugBank 6.0: the DrugBank Knowledgebase for 2024
Knox, C., Wilson, M., Klinger, C. M., Franklin, M., Oler, E., Wilson, A., Pon, A., Cox, J., Chin, N. E. (., Strawbridge, S. A., et al. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkad976 · Cited by 1,727
Self-citationOughtred, R., Rust, J., Chang, C., Breitkreutz, B., Stark, C., Willems, A., Boucher, L., Leung, G., Kolas, N., Zhang, F., et al. (2021) · Protein Science · doi:10.1002/pro.3978 · Cited by 1,858
Open Graph Benchmark: Datasets for Machine Learning on Graphs
Hu, W., Fey, M., Žitnik, M., Dong, Y., Ren, H., Liu, B., Catasta, M., & Leskovec, J. (2020) · arXiv (Cornell University) · doi:10.48550/arxiv.2005.00687 · Cited by 470
“This may result in techniques specialised for sparse link inference that are not generalizable to domains with dense graphs, such as the protein-protein association graphs and drug-drug interaction networks typically found in biology and medicine (Szklarczyk et al., 2019; Wishart et al., 2018; Davis et al., 2019; Szkl…”
BackgroundMethodInfluentialiDEP: an integrated web application for differential expression and pathway analysis of RNA-Seq data
Ge, S. X., Son, E. W., & Yao, R. (2018) · BMC Bioinformatics · doi:10.1186/s12859-018-2486-6 · Cited by 1,661
Burley, S. K., Bhikadiya, C., Bi, C., Bittrich, S., Chen, L., Crichlow, G. V., Christie, C. H., Dalenberg, K., Di Costanzo, L., Duarte, J. M., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkaa1038 · Cited by 1,581
Mullins, N., Forstner, A. J., O’Connell, K. S., Coombes, B., Coleman, J. R. I., Qiao, Z., Als, T. D., Bigdeli, T. B., Børte, S., Bryois, J., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00857-4 · Cited by 1,517
The BioGRID interaction database: 2019 update
Oughtred, R., Stark, C., Breitkreutz, B.-J., Rust, J., Boucher, L., Chang, C., Kolas, N., O’Donnell, L., Leung, G., McAdam, R., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1079 · Cited by 1,473
“To extend our curation breadth to chemical interactions and facilitate networkbased approaches to drug discovery, BioGRID has incorporated chemical–protein interaction records from DrugBank (60) and now manually curates small molecule–gene and –protein interactions.”
MethodArtificial intelligence to deep learning: machine intelligence approach for drug discovery
Gupta, R., Srivastava, D., Sahu, M., Tiwari, S., Ambasta, R. K., & Kumar, P. (2021) · Molecular Diversity · doi:10.1007/s11030-021-10217-3 · Cited by 1,473
Olson, R. D., Assaf, R., Brettin, T., Conrad, N., Cucinell, C., Davis, J. J., Dempsey, D. M., Dickerman, A., Dietrich, E. M., Kenyon, R. W., et al. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkac1003 · Cited by 1,260
Burley, S. K., Berman, H. M., Bhikadiya, C., Bi, C., Chen, L., Di Costanzo, L., Christie, C., Dalenberg, K., Duarte, J. M., Dutta, S., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1004 · Cited by 1,243
Mapping human microbiome drug metabolism by gut bacteria and their genes
Zimmermann, M., Zimmermann-Kogadeeva, M., Wegmann, R., & Goodman, A. L. (2019) · Nature · doi:10.1038/s41586-019-1291-3 · Cited by 1,160
Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma
Gao, Q., Zhu, H., Dong, L., Shi, W., Chen, R., Song, Z., Huang, C., Li, J., Dong, X., Zhou, Y., et al. (2019) · Cell · doi:10.1016/j.cell.2019.08.052 · Cited by 1,096
Self-citationDrug discovery with explainable artificial intelligence
Jiménez-Luna, J., Grisoni, F., & Schneider, G. (2020) · Nature Machine Intelligence · doi:10.1038/s42256-020-00236-4 · Cited by 1,063
Zhao, L., Zhang, H., Li, N., Chen, J., Xu, H., Wang, Y., & Liang, Q. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116306 · Cited by 963
Wightman, D. P., Jansen, I. E., Savage, J. E., Shadrin, A. A., Bahrami, S., Holland, D., Rongve, A., Børte, S., Winsvold, B. S., Drange, O. K., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00921-z · Cited by 1,011
Genomic atlas of the plasma metabolome prioritizes metabolites implicated in human diseases
Chen, Y., Lu, T., Pettersson-Kymmer, U., Stewart, I. D., Butler-Laporte, G., Nakanishi, T., Cerani, A., Liang, K. Y. H., Yoshiji, S., Willett, J. D. S., et al. (2023) · Nature Genetics · doi:10.1038/s41588-022-01270-1 · Cited by 969
Integration of the Drug–Gene Interaction Database (DGIdb 4.0) with open crowdsource efforts
Freshour, S. L., Kiwala, S., Cotto, K. C., Coffman, A. C., McMichael, J. F., Song, J. J., Griffith, M., Griffith, O. L., & Wagner, A. H. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkaa1084 · Cited by 998
BIOPEP-UWM Database of Bioactive Peptides: Current Opportunities
Minkiewicz, P., Iwaniak, A., & Darewicz, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235978 · Cited by 958
Burley, S. K., Bhikadiya, C., Bi, C., Bittrich, S., Chao, H., Chen, L., Craig, P. A., Crichlow, G. V., Dalenberg, K., Duarte, J. M., et al. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkac1077 · Cited by 887
ADMET modeling approaches in drug discovery
Ferreira, L. L. G., & Andricopulo, A. D. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.03.015 · Cited by 825
ETCM: an encyclopaedia of traditional Chinese medicine
Xu, H.-Y., Zhang, Y.-Q., Liu, Z.-M., Chen, T., Lv, C.-Y., Tang, S.-H., Zhang, X.-B., Zhang, W., Li, Z.-Y., Zhou, R.-R., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky987 · Cited by 828
“The therapeutic targets in the DrugBank database (17) of known drugs are considered as the candidate targets of the herbal ingredients with Tanimoto Scores >0.”
BackgroundU.S. FDA Approved Drugs from 2015–June 2020: A Perspective
Bhutani, P., Joshi, G., Raja, N., Bachhav, N., Rajanna, P. K., Bhutani, H., Paul, A. T., & Kumar, R. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01786 · Cited by 815
Casañal, A., Lohkamp, B., & Emsley, P. (2020) · Protein Science · doi:10.1002/pro.3791 · Cited by 800
Wang, Y., Zhang, S., Li, F., Zhou, Y., Zhang, Y., Wang, Z., Zhang, R., Zhu, J., Ren, Y., Tan, Y., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz981 · Cited by 794
Gehringer, M., & Laufer, S. A. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01153 · Cited by 714
ADMET-score – a comprehensive scoring function for evaluation of chemical drug-likeness
Guan, L., Yang, H., Cai, Y., Sun, L., Di, P., Li, W., Liu, G., & Tang, Y. (2019) · MedChemComm · doi:10.1039/c8md00472b · Cited by 712
A deep proteome and transcriptome abundance atlas of 29 healthy human tissues
Wang, D., Eraslan, B., Wieland, T., Hallström, B., Hopf, T., Zolg, D. P., Zecha, J., Asplund, A., Li, L., Meng, C., et al. (2019) · Molecular Systems Biology · doi:10.15252/msb.20188503 · Cited by 750
“Drug target genes (n=784) were obtained from Drugbank (Wishart et al. 2018) and restricted to proteins directly related to the mechanism of action for at least one of the associated drugs.”
MethodZheng, S., Wang, W., Aldahdooh, J., Malyutina, A., Shadbahr, T., Tanoli, Z., Pessia, A., & Tang, J. (2022) · Genomics, Proteomics & Bioinformatics · doi:10.1016/j.gpb.2022.01.004 · Cited by 733
QA-GNN: Reasoning with Language Models and Knowledge Graphs for Question Answering
Yasunaga, M., Ren, H., Bosselut, A., Liang, P., & Leskovec, J. (2021) · Proceedings of the 2021 Conference of the North American Chapter of the Association for Computational Linguistics: Human Language Technologies · doi:10.18653/v1/2021.naacl-main.45 · Cited by 522
HERB: a high-throughput experiment- and reference-guided database of traditional Chinese medicine
Fang, S., Dong, L., Liu, L., Guo, J., Zhao, L., Zhang, J., Bu, D., Liu, X., Huo, P., Cao, W., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkaa1063 · Cited by 690
Solid Lipid Nanoparticles for Drug Delivery: Pharmacological and Biopharmaceutical Aspects
Scioli Montoto, S., Muraca, G., & Ruiz, M. E. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.587997 · Cited by 652
“These are very promising results taking into consideration that, when administered as conventional formulations, the oral BA of these four drugs is in the range of 5-20% (Wishart et al., 2018).”
BackgroundG protein-coupled receptors: structure- and function-based drug discovery
Yang, D., Zhou, Q., Labroska, V., Qin, S., Darbalaei, S., Wu, Y., Yuliantie, E., Xie, L., Tao, H., Cheng, J., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00435-w · Cited by 632
TTD: Therapeutic Target Database describing target druggability information
Zhou, Y., Zhang, Y., Zhao, D., Yu, X., Shen, X., Zhou, Y., Wang, S., Qiu, Y., Chen, Y., & Zhu, F. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkad751 · Cited by 645
“Some describe pharmacological information on drugs, such as DrugBank ( 11 ), DrugCentral ( 12 ), Super-DRUG2 ( 13 ), DrugMap ( 14 ) and DRESIS ( 15 ); some others focus on presenting therapeutic targets, such as TTD ( 16 ) and Open Target ( 17 ); the remaining offer general molecule and bioactivity…”
BackgroundUse of molecular docking computational tools in drug discovery
(2021) · Progress in Medicinal Chemistry · doi:10.1016/bs.pmch.2021.01.004 · Cited by 621
Deep learning improves prediction of drug–drug and drug–food interactions
Ryu, J. Y., Kim, H. U., & Lee, S. Y. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1803294115 · Cited by 655
Zhou, Y., Zhang, Y., Lian, X., Li, F., Wang, C., Zhu, F., Qiu, Y., & Chen, Y. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkab953 · Cited by 665
Sabe, V. T., Ntombela, T., Jhamba, L. A., Maguire, G. E. M., Govender, T., Naicker, T., & Kruger, H. G. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113705 · Cited by 625
Structure-Based Virtual Screening: From Classical to Artificial Intelligence
Maia, E. H. B., Assis, L. C., de Oliveira, T. A., da Silva, A. M., & Taranto, A. G. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00343 · Cited by 588
“, 2019), Drugbank (Wishart et al., 2018), and Our Own Molecular Targets (OOMT) (Carregal et al.”
BackgroundStroke genetics informs drug discovery and risk prediction across ancestries
Mishra, A., Malik, R., Hachiya, T., Jürgenson, T., Namba, S., Posner, D. C., Kamanu, F. K., Koido, M., Le Grand, Q., Shi, M., et al. (2022) · Nature · doi:10.1038/s41586-022-05165-3 · Cited by 600
“The GIGASTROKE-based iPGS model showed a stronger association with AIS and a larger improvement in predictive ability compared with the MEGASTROKE-based iPGS model in both MVP and SIREN (Supplementary Tables 49 and 51).”
InfluentialNetwork Pharmacology Approach for Medicinal Plants: Review and Assessment
Noor, F., Tahir ul Qamar, M., Ashfaq, U. A., Albutti, A., Alwashmi, A. S. S., & Aljasir, M. A. (2022) · Pharmaceuticals · doi:10.3390/ph15050572 · Cited by 540
Rare variant contribution to human disease in 281,104 UK Biobank exomes
Wang, Q., Dhindsa, R. S., Carss, K., Harper, A. R., Nag, A., Tachmazidou, I., Vitsios, D., Deevi, S. V. V., Mackay, A., Muthas, D., et al. (2021) · Nature · doi:10.1038/s41586-021-03855-y · Cited by 604
Comprehensive quantification of fuel use by the failing and nonfailing human heart
Murashige, D., Jang, C., Neinast, M., Edwards, J. J., Cowan, A., Hyman, M. C., Rabinowitz, J. D., Frankel, D. S., & Arany, Z. (2020) · Science · doi:10.1126/science.abc8861 · Cited by 580
Proteogenomic characterization of pancreatic ductal adenocarcinoma
Cao, L., Huang, C., Cui Zhou, D., Hu, Y., Lih, T. M., Savage, S. R., Krug, K., Clark, D. J., Schnaubelt, M., Chen, L., et al. (2021) · Cell · doi:10.1016/j.cell.2021.08.023 · Cited by 578
A drug-likeness toolbox facilitates ADMET study in drug discovery
Jia, C.-Y., Li, J.-Y., Hao, G.-F., & Yang, G.-F. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2019.10.014 · Cited by 547
WANG, X., WANG, Z.-Y., ZHENG, J.-H., & LI, S. (2021) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(21)60001-8 · Cited by 545
deepDR: a network-based deep learning approach to in silico drug repositioning
Zeng, X., Zhu, S., Liu, X., Zhou, Y., Nussinov, R., & Cheng, F. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz418 · Cited by 535
Mapping the landscape of Artificial Intelligence applications against COVID-19
Bullock, J., Luccioni, A., Hoffman Pham, K., Sin Nga Lam, C., & Luengo-Oroz, M. (2020) · Journal of Artificial Intelligence Research · doi:10.1613/jair.1.12162 · Cited by 348
Djoumbou-Feunang, Y., Fiamoncini, J., Gil-de-la-Fuente, A., Greiner, R., Manach, C., & Wishart, D. S. (2019) · Journal of Cheminformatics · doi:10.1186/s13321-018-0324-5 · Cited by 508
“Potential applications might include the in silico expansion of chemical databases of drugs (e.g. DrugBank [38]), food compounds (e.g. FooDB [39]), phytochemicals (e.g. PhytoHub [40]), environmental contaminants (e.g. ContaminantDB [41], T3DB [42], the CompTox Database [43]), organism-specific…”
BackgroundMethodInfluentialSelf-citationBuilding a knowledge graph to enable precision medicine
Chandak, P., Huang, K., & Zitnik, M. (2023) · Scientific Data · doi:10.1038/s41597-023-01960-3 · Cited by 522
Review on natural products databases: where to find data in 2020
Sorokina, M., & Steinbeck, C. (2020) · Journal of Cheminformatics · doi:10.1186/s13321-020-00424-9 · Cited by 485
Zhou, N., Yuan, X., Du, Q., Zhang, Z., Shi, X., Bao, J., Ning, Y., & Peng, L. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkac935 · Cited by 498
“Drug information is retrieved on request from the DrugBank database via UniProt’s REST API (43).”
MethodA review on machine learning approaches and trends in drug discovery
Carracedo-Reboredo, P., Liñares-Blanco, J., Rodríguez-Fernández, N., Cedrón, F., Novoa, F. J., Carballal, A., Maojo, V., Pazos, A., & Fernandez-Lozano, C. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.08.011 · Cited by 472
“Currently, there are numerous public repositories 1 that store a large amount of useful data for the field of drug discovery, such as DrugBank [12], PubChem [13], ChEMBL [14] or ZINC [15].”
BackgroundUhlén, M., Karlsson, M. J., Hober, A., Svensson, A.-S., Scheffel, J., Kotol, D., Zhong, W., Tebani, A., Strandberg, L., Edfors, F., et al. (2019) · Science Signaling · doi:10.1126/scisignal.aaz0274 · Cited by 495
Computational Approaches in Preclinical Studies on Drug Discovery and Development
Wu, F., Zhou, Y., Li, L., Shen, X., Chen, G., Wang, X., Liang, X., Tan, M., & Huang, Z. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00726 · Cited by 446
“DrugBank, a comprehensive database, integrated thousands of well-studied drugs and drug targets with their physical, chemical, biological, and pharmaceutical data (Wishart et al., 2006, 2008).”
BackgroundInfluentialArtificial intelligence in cancer target identification and drug discovery
You, Y., Lai, X., Pan, Y., Zheng, H., Vera, J., Liu, S., Deng, S., & Zhang, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00994-0 · Cited by 435
“…drug damages an entire organism, an organism ’ s substructure, or an organ. targets 34,54,57,74,80 , the principles and theory of commonly used arti fi cial intelligence biology analysis algorithms 83 – 91 , and the arti fi cial intelligence for arti fi cial intelligence biology analysis 42,195,213 .”
BackgroundPotential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines
Liu, X., & Wang, X.-J. (2020) · Journal of Genetics and Genomics · doi:10.1016/j.jgg.2020.02.001 · Cited by 464
Big data and artificial intelligence modeling for drug discovery
Zhu, H. (2020) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010919-023324 · Cited by 455
“For example, DrugBank (https://www.drugbank.ca) is a publicly available database containing all approved drugs with their mechanisms, interactions, and relevant targets (49).”
BackgroundDeciphering osteoarthritis genetics across 826,690 individuals from 9 populations
Boer, C. G., Hatzikotoulas, K., Southam, L., Stefánsdóttir, L., Zhang, Y., Coutinho de Almeida, R., Wu, T. T., Zheng, J., Hartley, A., Teder-Laving, M., et al. (2021) · Cell · doi:10.1016/j.cell.2021.07.038 · Cited by 434
“Wishart et al., 2018 https://go.drugbank.com Resource related to eQTL colocalization, causal inference and tissue specificity analyses: GTEx.”
InfluentialRecent developments of HDAC inhibitors: Emerging indications and novel molecules
Bondarev, A. D., Attwood, M. M., Jonsson, J., Chubarev, V. N., Tarasov, V. V., & Schiöth, H. B. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14889 · Cited by 416
ADMET-AI: a machine learning ADMET platform for evaluation of large-scale chemical libraries
Swanson, K., Walther, P., Leitz, J., Mukherjee, S., Wu, J. C., Shivnaraine, R. V., & Zou, J. (2024) · Bioinformatics · doi:10.1093/bioinformatics/btae416 · Cited by 372
“1.10) (Wishart et al. 2018) that have obtained regulatory approval as a reference set (Supplementary Table S2).”
BackgroundInfluentialDrug repurposing for cancer therapy
Xia, Y., Sun, M., Huang, H., & Jin, W.-L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01808-1 · Cited by 443
Machine learning approaches and databases for prediction of drug–target interaction: a survey paper
Bagherian, M., Sabeti, E., Wang, K., Sartor, M. A., Nikolovska-Coleska, Z., & Najarian, K. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbz157 · Cited by 429
“The drug information and drug targets are from previous research [291] and DrugBank [244].”
BackgroundMethodInfluentialIMPPAT 2.0: An Enhanced and Expanded Phytochemical Atlas of Indian Medicinal Plants
Vivek-Ananth, R. P., Mohanraj, K., Sahoo, A. K., & Samal, A. (2023) · ACS Omega · doi:10.1021/acsomega.3c00156 · Cited by 372
Graph convolutional networks for computational drug development and discovery
Sun, M., Zhao, S., Gilvary, C., Elemento, O., Zhou, J., & Wang, F. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbz042 · Cited by 413
Future Antimicrobials: Natural and Functionalized Phenolics
Lobiuc, A., Pavăl, N.-E., Mangalagiu, I. I., Gheorghiță, R., Teliban, G.-C., Amăriucăi-Mantu, D., & Stoleru, V. (2023) · Molecules · doi:10.3390/molecules28031114 · Cited by 418
“Current databases indicate that phenolic compounds such as rutin, quercetin, diosmin, hesperitin and genistein, may interact with a large number of compounds, many of which are involved in microbial/bacterial metabolism [50].”
BackgroundMuralidharan, N., Sakthivel, R., Velmurugan, D., & Gromiha, M. M. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1752802 · Cited by 415
“The SMILES of the three drugs lopi-navir, oseltamivir and ritonavir were obtained from DrugBank (Wishart et al., 2018) and their accession numbers are DB01601, DB00198, and DB00503 respectively.”
MethodArtificial Intelligence for Drug Toxicity and Safety
Basile, A. O., Yahi, A., & Tatonetti, N. P. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.07.005 · Cited by 363
Graph embedding on biomedical networks: methods, applications and evaluations
Yue, X., Wang, Z., Huang, J., Parthasarathy, S., Moosavinasab, S., Huang, Y., Lin, S. M., Zhang, W., Zhang, P., & Sun, H. (2020) · Bioinformatics · doi:10.1093/bioinformatics/btz718 · Cited by 386
“We collect verified DDIs from DrugBank (Wishart et al., 2017), a comprehensive and freely accessible online database that contains detailed information about drugs and drug”
Jarada, T. N., Rokne, J. G., & Alhajj, R. (2020) · Journal of Cheminformatics · doi:10.1186/s13321-020-00450-7 · Cited by 384
“Table 3 provides examples of drug repositioning applications in various disease areas and related therapeutics retrieved from Drugs@ FDA database [91] and DrugBank [82].”
BackgroundOne molecular fingerprint to rule them all: drugs, biomolecules, and the metabolome
Capecchi, A., Probst, D., & Reymond, J.-L. (2020) · Journal of Cheminformatics · doi:10.1186/s13321-020-00445-4 · Cited by 363
Unexplored therapeutic opportunities in the human genome
Oprea, T. I., Bologa, C. G., Brunak, S., Campbell, A., Gan, G. N., Gaulton, A., Gomez, S. M., Guha, R., Hersey, A., Holmes, J., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.14 · Cited by 378
Mechanisms of increased bioavailability through amorphous solid dispersions: a review
Schittny, A., Huwyler, J., & Puchkov, M. (2020) · Drug Delivery · doi:10.1080/10717544.2019.1704940 · Cited by 343
Single-cell meta-analysis of SARS-CoV-2 entry genes across tissues and demographics
Muus, C., Luecken, M. D., Eraslan, G., Sikkema, L., Waghray, A., Heimberg, G., Kobayashi, Y., Vaishnav, E. D., Subramanian, A., Smillie, C., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-01227-z · Cited by 348
Khan, R. J., Jha, R. K., Amera, G. M., Jain, M., Singh, E., Pathak, A., Singh, R. P., Muthukumaran, J., & Singh, A. K. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1753577 · Cited by 343
“One hundred twenty-three entries belonging to the category of antiviral drugs were downloaded from DrugBank database (Wishart et al., 2018) and were subsequently converted into a single structure data file (SDF) library (see supplementary data, Table 3).”
MethodIdentifying drug–target interactions based on graph convolutional network and deep neural network
Zhao, T., Hu, Y., Valsdottir, L. R., Zang, T., & Peng, J. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa044 · Cited by 332
Chemotherapy-Induced Peripheral Neuropathy: Epidemiology, Pathomechanisms and Treatment
Burgess, J., Ferdousi, M., Gosal, D., Boon, C., Matsumoto, K., Marshall, A., Mak, T., Marshall, A., Frank, B., Malik, R. A., et al. (2021) · Oncology and Therapy · doi:10.1007/s40487-021-00168-y · Cited by 306
Constructing knowledge graphs and their biomedical applications
Nicholson, D. N., & Greene, C. S. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.05.017 · Cited by 299
Visualization of very large high-dimensional data sets as minimum spanning trees
Probst, D., & Reymond, J.-L. (2020) · Journal of Cheminformatics · doi:10.1186/s13321-020-0416-x · Cited by 295
Pathway Commons 2019 Update: integration, analysis and exploration of pathway data
Rodchenkov, I., Babur, O., Luna, A., Aksoy, B. A., Wong, J. V., Fong, D., Franz, M., Siper, M. C., Cheung, M., Wrana, M., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz946 · Cited by 311
Zeng, X., Xiang, H., Yu, L., Wang, J., Li, K., Nussinov, R., & Cheng, F. (2022) · Nature Machine Intelligence · doi:10.1038/s42256-022-00557-6 · Cited by 308
“We focused on 2,501 US Food and Drug Administration-approved drugs from DrugBank 56 to identify ImageMol-predicted 3CL protease inhibitors as drugs repurposable for COVID-19 using a drug repurposing strategy 52 .”
MethodRuben, M. D., Wu, G., Smith, D. F., Schmidt, R. E., Francey, L. J., Lee, Y. Y., Anafi, R. C., & Hogenesch, J. B. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat8806 · Cited by 314
“We used DrugBank (21) version 5.0.11, released on 20 December 2017, to identify genes whose protein products are targets, transporters, carriers, or enzymes linked to specific drug entities.”
InfluentialUtilizing graph machine learning within drug discovery and development
Gaudelet, T., Day, B., Jamasb, A. R., Soman, J., Regep, C., Liu, G., Hayter, J. B. R., Vickers, R., Roberts, C., Tang, J., et al. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab159 · Cited by 313
Synthetic organic chemistry driven by artificial intelligence
de Almeida, A. F., Moreira, R., & Rodrigues, T. (2019) · Nature Reviews Chemistry · doi:10.1038/s41570-019-0124-0 · Cited by 303
Zhou, Z., Luo, M., Chen, X., Yin, Y., Xiong, X., Wang, R., & Zhu, Z.-J. (2020) · Nature Communications · doi:10.1038/s41467-020-18171-8 · Cited by 290
Erratum: Unexplored therapeutic opportunities in the human genome
Oprea, T. I., Bologa, C. G., Brunak, S., Campbell, A., Gan, G. N., Gaulton, A., Gomez, S. M., Guha, R., Hersey, A., Holmes, J., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.52 · Cited by 311
Exome sequencing of 20,791 cases of type 2 diabetes and 24,440 controls
Platform, B. G., Flannick, J., DiscovEHR Collaboration, CHARGE, LuCamp, ProDiGY, GoT2D, ESP, SIGMA-T2D, T2D-GENES, et al. (2019) · Nature · doi:10.1038/s41586-019-1231-2 · Cited by 304
Xu, Z., Shi, D., Han, J.-B., Ling, Y., Jiang, X., Lu, X., Li, C., Gong, L., Ge, G., Zhang, Y., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01429-0 · Cited by 301
Self-citationVassetti, D., Pagliai, M., & Procacci, P. (2019) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.8b01039 · Cited by 281
“20 For the modeling of liquid 1-octanol in standard conditions with GAFF2 and OPLS-AA, we have adopted the corresponding PrimaDORAC and LigParGen generated parameterizations.”
MethodGe, Y., Tian, T., Huang, S., Wan, F., Li, J., Li, S., Wang, X., Yang, H., Hong, L., Wu, N., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00568-6 · Cited by 300
“Such a tissue speci fi c enrichment in lung may bring an extra advantage for CVL218 to be used for the anti-SARS-CoV-2 purpose, as lung is the therapeutically targeted tissue for COVID-19.”
BackgroundMethodInfluentialArtificial intelligence for drug discovery: Resources, methods, and applications
Chen, W., Liu, X., Zhang, S., & Chen, S. (2023) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2023.02.019 · Cited by 273
Shafiei, M., Peyton, L., Hashemzadeh, M., & Foroumadi, A. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104240 · Cited by 295
“Moreover, some new structures like UR-9660 (43) and SDZ-89–485 (45) are in preclinical stages [18–20 Many triazole alcohol derivations have been investigated and several new and known scaffolds incorporated into their structures are assessed in terms of their antifungal activity [84–86].”
A Guide to In Silico Drug Design
Chang, Y., Hawkins, B. A., Du, J. J., Groundwater, P. W., Hibbs, D. E., & Lai, F. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics15010049 · Cited by 250
Metadata
- Authors
- Wishart, D. S., Feunang, Y. D., Guo, A. C., Lo, E. J., Marcu, A., Grant, J. R., Sajed, T., Johnson, D., Li, C., Sayeeda, Z., Assempour, N., Iynkkaran, I., Liu, Y., Maciejewski, A., Gale, N., Wilson, A., Chin, L., Cummings, R., Le, D., Pon, A., Knox, C., & Wilson, M.
- Affiliations
- University of Alberta (CA)
- Corresponding author
- Wishart, David S
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-11-08
- Volume
- 46
- Issue
- D1
- Pages
- D1074-D1082
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- PMC
- PMC5753335
- OpenAlex
- W2767891136
- Cited by
- 8,404
- References
- 22
- Citations by year
- 2026: 617 · 2025: 929 · 2024: 1327 · 2023: 1363 · 2022: 1322 · 2021: 1175 · 2020: 957 · 2019: 502 · 2018: 201 · 2017: 5
- FWCI
- 343.79
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Nucleic Acids Research (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Genome Canada
- Genome Alberta
- Health Canada
- Canadian Institutes of Health Research
- National Human Genome Research Institute
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Health Informatics › Biomedical Text Mining and Ontologies
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- DrugBank, drug databases, drug-drug interactions, food-drug interactions, therapeutic target, drug mechanisms, drug indications, pharmacometabolomics, pharmacoproteomics, drug repurposing, clinical trials, investigational drugs
- MeSH terms
- Drug Interactions, User-Computer Interface, Food-Drug Interactions, Polymorphism, Single Nucleotide, Metabolome, Transcriptome, Databases, Pharmaceutical
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

